mavacoxib

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The inducible inflammatory enzyme cyclooxygenase-2 (COX-2) and its product prostaglandin E2 (PGE2 ) are prominent tumour… (More)
Is this relevant?
2015
2015
A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2014
2014
NSAIDs are the cornerstone of medical management of canine osteoarthritis (OA). Meloxicam is a daily-administered NSAID widely… (More)
  • table 2
  • table 3
  • table 4
  • table 6
  • figure 1
Is this relevant?
2014
2014
BACKGROUND The NSAID mavacoxib (Trocoxcil™) is a recently described selective COX-2 inhibitor used for the management of… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Osteosarcoma is the most common primary bone tumour of both children and dogs. It is an aggressive tumour in both species with a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Received: Revised: Accepted: October 11, 2012 December 12, 2012 December 17, 2012 The aim of this study was to assess the… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2011
2011
Mavacoxib (Trocoxil™) is an oral long-acting COX-2 inhibitor approved for the treatment of osteoarthritis in dogs. Two field… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
2010
2010
The pharmacokinetics of mavacoxib were evaluated in an absolute bioavailability study, a dose-proportionality study and a multi… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2008
2008
  • 2008
Trocoxil, chewable tablets for dogs, contain mavacoxib as the active substance and the triangular shaped tablets are presented in… (More)
Is this relevant?